Cellular and molecular aspects of drugs of the future: oxaliplatin

@article{Francesco2002CellularAM,
  title={Cellular and molecular aspects of drugs of the future: oxaliplatin},
  author={Angela Maria Di Francesco and Antonietta Ruggiero and Riccardo Riccardi},
  journal={Cellular and Molecular Life Sciences CMLS},
  year={2002},
  volume={59},
  pages={1914-1927}
}
Oxaliplatin (Eloxatine) is a third-generation platinum compound which has shown a wide antitumour effect both in vitro and in vivo, a better safety profile than cisplatin and a lack of cross-resistance with cisplatin and carboplatin. In this scenario, oxaliplatin may represent an innovative and challenging drug extending the antitumour activity in diseases such as gastrointestinal cancer that are not usually sensitive to these coordination complexes. Oxaliplatin has a non-hydrolysable… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Platinum-based drugs: past, present and future

Cancer Chemotherapy and Pharmacology • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 129 references

Drugs of the Future : Review 1927 high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum - DNA adducts

G. Obmolova, C. Ban, P. Hsieh, W Yang
2002

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer

J. PiccartM., H. Lamb, B. VermokenJ.
Ann . Oncol • 2001

Similar Papers

Loading similar papers…